Sven Francque and William Alazawi join the Surfers to discuss challenges in creating efficacy endpoints, and also areas where development has improved since 2020during MASH Drug Development.
Sven Francque and William Alazawi join the Surfers to discuss challenges in proper scoring and categorization of efficacy endpoints during MASH Drug Development.
Sven Francque joins guest William Alazawi and the Surfers to discuss high points from his 2023 article on the MASH drug development graveyard in 2023
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
This 2023 conversation raises the question of prescribing MASH drugs adjunctive to other therapies, most notably HCC.
This final conversation touches on prescribing models and the increasing challenge keeping patients in long-term clinical trials, after which Roger Green asks a final question.
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton, Jörn Schattenberg and Louise Campbell each identify a specific paper or event they consider exciting and important.
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
